Cytospire Therapeutics secures £3.4m Series A for cancer antibody development

Altrincham-based Cytospire Therapeutics has secured £3.4m in Series A funding to advance its development of next-generation multispecific antibodies. The company focuses on pan-gamma delta T cell engagers designed to treat cancer, including solid and hematological malignancies, and autoimmune diseases.

The latest capital injection (filed in May) follows a series of funding activities earlier this year. This includes a £7.3m round in March that valued the business at £38.3m and a £4.7m round also in March at a £31m valuation. Prior to these Series A tranches, Cytospire Therapeutics raised seed funding of £3m in October 2024, £7m in November 2023, and £5m in May 2023.

The lead program at the firm, CYT X300, is being developed for the treatment of EGFR-positive solid tumors. Targeted applications include colorectal, head and neck, and non-small cell lung cancers. The technology aims to stimulate the activity of both the innate and adaptive immune systems.

Financial records for the year ended 31 March 2025 show the company recorded a £4.3m loss. While statutory accounts list a headcount of 12 staff, recent LinkedIn data indicates the team has grown to approximately 20 employees. Cytospire Therapeutics was incorporated in 2023.

Recent board changes include the appointment of Alexis Vandier as a director in May. This follows the appointments of Dr Carmine Daniel Circelli and Dr Anna Emilia Gran to the board in March.